4 results
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
4.1 Primary Objective• To determine the MTD and to establish the safety profile of enapotamab vedotin in a mixed population of patients with specified solid tumors. 4.2 Secondary Objectives• To evaluate the safety laboratory parameters of enapotamab…
To investigate whether daily electrical stimulation of gluteal and hamstring muscles combined with usual care is more effective than only usual in individuals with chronic SCI who often have PU*s and/or are at high of recurring PU*s regarding: 1)…